UNSPSC 51292202: Flubepride

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UU4X6T9FT5. European Medicines Agency schedules Flubepride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07667MIG. Flubepride generally arises in the molecular formula C20H24FN3O4S.

UNSPSC 51292202 Flubepride is a Commodity code that captures pharmaceutical products — primarily naloxone, drug deactivation systems, generic multi-source medications, and over-the-counter products — that state and local health agencies, departments of human services, and cooperative purchasing alliances procure to support community health initiatives, pharmacy benefit programs, and emergency response operations. State and local governments buying under this code range from county health departments managing naloxone distribution to statewide health commissions designing pharmacy benefit programs to multistate cooperative purchasing organizations aggregating demand across multiple jurisdictions. The work includes competitive bidding for emergency opioid-reversal supplies, market-intelligence gathering to reshape direct pharmacy procurement models, and multi-vendor contracting for generic pharmaceuticals distributed through established wholesale channels.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling the state's intent to restructure how it contracts for medications outside traditional pharmacy benefit manager and group purchasing organization relationships. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with a response deadline of March 26, 2026 and contract effectiveness targeted for July 1, 2026. Vendors must maintain relationships with authorized wholesalers, comply with cGMP and Drug Supply Chain Security Act certifications, and accept a 3 percent administrative fee on all purchases.